Table 2. Assessment of dose-proportionality for pharmacokinetics of fluticasone, salmeterol, and tiotropium using power model regression.
| Study drug | Parameters | Slope (95% confidence interval) |
|---|---|---|
| Fluticasone | Cmax (pg/mL) | 0.8584 (0.6458 – 1.0710) |
| AUClast (h*pg/mL) | 0.8513 (0.6562 – 1.0463) | |
| AUCinf (h*pg/mL) | 0.8466 (0.6528 – 1.0403) | |
| Salmeterol | Cmax (pg/mL) | 0.9410 (0.6467 – 1.2353) |
| AUClast (h*pg/mL) | 1.2010 (0.9709 – 1.4311) | |
| AUCinf (h*pg/mL) | 1.1616 (0.9457 – 1.3776) | |
| Tiotropium | Cmax (pg/mL) | 1.1452 (0.7355 – 1.5548) |
| AUC0-30min (h*pg/mL) | 1.0674 (0.7143 – 1.4206) | |
| AUClast (h*pg/mL) | 2.1977 (1.6239 – 2.7716) | |
| AUCinf (h*pg/mL) | 2.7928 (1.8118 – 3.7739) |
Power model: ln(Y) = (Intercept) + (Slope) × ln(Dose), Y: pharmacokinetic parameter. Cmax, maximum plasma concentration; AUClast, area under the plasma concentration-time curve from time zero to the last observed time point; AUCinf, AUC from time zero to infinity; AUC0-30min, AUC from time zero to 30 minute.